Merck Provides U.S. Regulatory Update on Gefapixant

RAHWAY, N.J.--(BUSINESS WIRE) December 20, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news